TrialBlood advances2022
A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease.
Aleksandr Lazaryan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
this paperpooled itcites it